Literature DB >> 33426889

Ifenprodil Stereoisomers: Synthesis, Absolute Configuration, and Correlation with Biological Activity.

Elena Bechthold1,2, Julian A Schreiber2,3, Kirstin Lehmkuhl2, Bastian Frehland2, Dirk Schepmann2, Freddy A Bernal4, Constantin Daniliuc5, Inés Álvarez6, Cristina Val Garcia7, Thomas J Schmidt4, Guiscard Seebohm1,3,7, Bernhard Wünsch1,2.   

Abstract

Ifenprodil (1) is a potent GluN2B-selective N-methyl-d-aspartate (NMDA) receptor antagonist that is used as a cerebral vasodilator and has been examined in clinical trials for the treatment of drug addiction, idiopathic pulmonary fibrosis, and COVID-19. To correlate biological data with configuration, all four ifenprodil stereoisomers were prepared by diastereoselective reduction and subsequent separation of enantiomers by chiral HPLC. The absolute configuration of ifenprodil stereoisomers was determined by X-ray crystal structure analysis of (1R,2S)-1a and (1S,2S)-1d. GluN2B affinity, ion channel inhibitory activity, and selectivity over α, σ, and 5-HT receptors were evaluated. (1R,2R)-Ifenprodil ((1R,2R)-1c) showed the highest affinity toward GluN2B-NMDA receptors (Ki = 5.8 nM) and high inhibition of ion flux in two-electrode voltage clamp experiments (IC50 = 223 nM). Whereas the configuration did not influence considerably the GluN2B-NMDA receptor binding, (1R)-configuration is crucial for elevated inhibitory activity. (1R,2R)-Configured ifenprodil (1R,2R)-1c exhibited high selectivity for GluN2B-NMDA receptors over adrenergic, serotonergic, and σ1 receptors.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33426889     DOI: 10.1021/acs.jmedchem.0c01912

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  Fisetin decreases the duration of ictal-like discharges in mouse hippocampal slices.

Authors:  Hilal Ozturk; Harun Basoglu; Nuri Yorulmaz; Selcen Aydin-Abidin; Ismail Abidin
Journal:  J Biol Phys       Date:  2022-08-10       Impact factor: 1.560

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.